

**PHARMACEUTICAL MARKETS
AND INSURANCE WORLDWIDE**

CONTENTS

LIST OF CONTRIBUTORS ix

OVERVIEW xiii

PART I: INTERNATIONAL REVIEWS

PHARMACEUTICAL POLICIES IN
EUROPEAN COUNTRIES 3
Pedro Pita Barros

INTERNATIONAL EXPERIENCE WITH
COMPARATIVE EFFECTIVENESS RESEARCH:
CASE STUDIES FROM ENGLAND/WALES AND
GERMANY 29
*John F. P. Bridges, Joshua P. Cohen,
Peter G. Grist and Axel C. Mühlbacher*

PART II: NATIONAL CASE STUDIES

PHARMACEUTICAL POLICY IN THE
NETHERLANDS: FROM PRICE
REGULATION TOWARDS MANAGED
COMPETITION 53
*Lieke H. H. M. Boonen, Stéphanie A. van der Geest,
Frederik T. Schut and Marco Varkevisser*

IMPACT OF PHARMACEUTICAL
REGULATION AND POLICIES ON
HEALTH SYSTEM PERFORMANCE
GOALS IN ISRAEL 77
Philip Sax and Amir Shmueli

GLOBAL BUDGETS AND PROVIDER INCENTIVES: HOSPITALS' DRUG EXPENDITURES IN TAIWAN	
<i>Shin-Yi Chou, Mary E. Deily, Hsien-Ming Lien and Jing Hua Zhang</i>	103
MEDICARE PART D TURNS FOUR: TRENDS IN PLAN DESIGN, ENROLLMENT, AND THE IMPACT OF THE PROGRAM ON BENEFICIARIES	
<i>Jack Hoadley and Kosali Simon</i>	123
PART III: U.S. STUDIES – FROM MARKETS TO POLICY INNOVATIONS	
DOES PRESCRIPTION DRUG ADHERENCE REDUCE HOSPITALIZATIONS AND COSTS? THE CASE OF DIABETES	
<i>William E. Encinosa, Didem Bernard and Avi Dor</i>	151
COST SHARING, BENEFIT DESIGN, AND ADHERENCE: THE CASE OF MULTIPLE SCLEROSIS	
<i>Avi Dor, Maureen J. Lage, Marcy L. Tarrant and Jane Castelli-Haley</i>	175
GENERIC UTILIZATION AND COST-SHARING FOR PRESCRIPTION DRUGS	
<i>Teresa Bernard Gibson, Catherine G. McLaughlin and Dean G. Smith</i>	195
DRUG PRICES, OUT-OF-POCKET PAYMENTS, AND INSURER COSTS: HOW DO PAYERS VARY?	
<i>Jie Chen and John A. Rizzo</i>	221
ADVERSE SELECTION AND THE EFFECT OF HEALTH INSURANCE ON UTILIZATION OF PRESCRIBED MEDICINE AMONG PATIENTS WITH CHRONIC CONDITIONS	
<i>Yuriy Pylypchuk</i>	233

THE EFFECT OF DRUG VINTAGE ON SURVIVAL: MICRO EVIDENCE FROM PUERTO RICO'S MEDICAID PROGRAM <i>Frank R. Lichtenberg</i>	273
--	-----

PART IV: SPECIAL TOPICS

RETAIL PHARMACY MARKET STRUCTURE AND INSURER-INDEPENDENT PHARMACY BARGAINING IN THE MEDICARE PART D ERA <i>Yang Xie, John M. Brooks, Julie M. Urmie and William R. Doucette</i>	295
PATENTS, INNOVATION, AND THE WELFARE EFFECTS OF MEDICARE PART D <i>Adam Gailey, Darius Lakdawalla and Neeraj Sood</i>	317